Clinical Trials Logo

Short Bowel Syndrome clinical trials

View clinical trials related to Short Bowel Syndrome.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06391762 Completed - Clinical trials for Short Bowel Syndrome

Level of Deprivation Assessment in a Population of Short-bowel Syndrome Patients With Intestinal Failure

PRECAR-SGC
Start date: December 28, 2023
Phase:
Study type: Observational

The association between social deprivation and chronic disease is regularly examined but there are no data available on patients with intestinal failure due to short bowel syndrome (SBS-IF). First, the investigators aim to characterize this population and then to assess if insecurity is associated with some disease criteria.

NCT ID: NCT06102668 Completed - Clinical trials for Short Bowel Syndrome

Survival and PN Dependence in SBS Patients

Start date: January 1, 2012
Phase:
Study type: Observational

Short bowel syndrome (SBS) is a rare condition resulting from the loss of portions of the small intestine, and can cause a spectrum of metabolic and physiologic disturbances.The objective of this study was to determine the longterm survival and parenteral nutrition dependence of adult patients with SBS.

NCT ID: NCT05706012 Completed - Clinical trials for Short Bowel Syndrome

Antithrombotic Management of Acute Mesenteric Ischaemia

Start date: June 30, 2023
Phase:
Study type: Observational

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

NCT ID: NCT05377112 Completed - Clinical trials for Enteric Hyperoxaluria

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

Start date: March 29, 2022
Phase: Early Phase 1
Study type: Interventional

Study SYNB8802-CP-002 is designed to assess safety, tolerability, and oxalate lowering, in subjects with a history of gastric bypass surgery or short-bowel syndrome. In addition, this study will explore other PD effects relative to baseline as well as predictors of efficacy and tolerability.

NCT ID: NCT05181085 Completed - Clinical trials for Short Bowel Syndrome

Study of NST-6179 in Healthy Subjects

Start date: December 7, 2021
Phase: Phase 1
Study type: Interventional

A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.

NCT ID: NCT05113082 Completed - Clinical trials for Short Bowel Syndrome (SBS)

Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil

Start date: May 21, 2022
Phase:
Study type: Observational

The main aim of this study is to capture management and treatment outcome data in participants with short bowel syndrome and chronic intestinal failure (SBS-IF) that underwent intestinal transplantation in Brazil. This study is about collecting data available in the participant's medical record and will also describe the demographic and clinical characteristics of these participants. No medication will be provided to participants in this study. Clinical data will be collected from a period up to 10 years before the day of the intestinal transplantation. No clinic visits will be required as part of participation in this study.

NCT ID: NCT05027308 Completed - Clinical trials for Short Bowel Syndrome

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Start date: January 4, 2022
Phase: Phase 3
Study type: Interventional

The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks. Participants may be able to repeat this treatment if they meet specific criteria. The study doctors will check for side effects from teduglutide until it becomes commercially available. The maximum duration of treatment is approximately 51.3 weeks.

NCT ID: NCT04991311 Completed - Clinical trials for Short Bowel Syndrome

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

EASE SBS 4
Start date: August 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS). The trial will also investigate whether glepaglutide is safe during long-term use. All participants in the trial will receive glepaglutide injections. Participants will have 14 visits with the study doctor. At 2 of these, participants will spend 48 hours at the trial site, one visit at the start of the trial and one after 24 weeks of treatment with glepaglutide. At all visits, participants will meet with trial staff and will have blood tests along with other clinical checks and tests done. Participants will be asked about their health and medical history.

NCT ID: NCT04981262 Completed - Clinical trials for Short Bowel Syndrome

Improved Quality of Life in Children With Intestinal Failure

Start date: September 2, 2021
Phase: N/A
Study type: Interventional

Children with intestinal failure have a lack of tolerance for food in the intestine. The children are dependent on intravenous nutrition over a long period of time period to ensure growth and development. The condition is characterized by bacterial overgrowth in the intestine, with nausea, vomiting, diarrhea and flatulence as physical symptoms. Mental health is affected in the form of lower quality of life, lack of school participation and less social contact with peers. The investigators own (unpublished) data show that children with intestinal failure have a lower quality of life than healthy people. Standard treatment is antibiotics, but the effect of these is short-lived, and many must have repeated courses. Prebiotics are indigestible carbohydrates (fiber) in foods that positively affect the bacterial flora and promote intestinal health. In this project the investigators want to see if supply of prebiotics can change the bacterial balance, reduce symptoms of bacterial overgrowth and increase quality of life. The study is unique, as Prebiotics have not previously been used in the treatment of intestinal failure. If successful, it can pave the way for a new and better treatment method that can potentially be transferred to other conditions with imbalance in the intestinal flora. The study is a randomized intervention study and is consist of two phases. In phase 1, the effect of 4 weeks of open intervention with prebiotics is studied to establish so-called "proof of concept". Data from phase 1 are used to look at connections between the composition of intestinal flora, nutritional status and bowel function. The intervention involves the use of a prebiotic product (Stimulance, Nutricia), which is added to childs regular food. In phase 2, patients are randomized into two groups. One group will continue with the product for 6 months, while the other group does not receive prebiotics.

NCT ID: NCT04964986 Completed - Clinical trials for Short Bowel Syndrome

Metabolic Balance Study of Apraglutide in Patients With SBS-IF and Colon-in-Continuity

STARSnutrition
Start date: June 14, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.